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Objective: Pseudoaneurysm (PSA) formation is a complication of hemodialysis access. Open repair requires PSA resection,
interposition graft placement, and insertion of a catheter as a bridge. Endovascular stent graft repair is an alternative that
permits immediate use of the access site. The objective of this study was to determine the efficacy of stent grafts for repair
of arteriovenous fistula and arteriovenous graft PSA.
Methods: A retrospective review of medical records from October 2007 to March 2011 revealed 24 patients with a PSA
who underwent endovascular repair using a stent graft. Indications for repair included PSAwith symptoms (n 11), PSA
with skin erosion (n 8), PSA with failed hemodialysis (n 3), and PSA after balloon angioplasty of a stenosis (n 2).
Outcome measures were technical success, 30-day and 180-day patency, secondary interventions, and complications. All
the statistical analyses were conducted by using software SAS 9.1 (SAS, SAS Institute, Gary, NC).
Results: Twenty-seven self-expanding stent grafts (Viabahn, W. L. Gore, n 25; Fluency, Bard, n 2) were used to treat
hemodialysis access (arteriovenous graft, n 13; arteriovenous fistula, n 11) PSA in 24 patients (16 females; mean age,
55.7 years; mean body mass index, 28.4; mean PSA diameter, 19.5 mm). Comorbidities included hypertension (n  22;
91.7%), diabetes mellitus (n  8; 33.3%), and coronary artery disease (n  4; 16.67%). The median time from access
creation to repair was 455 days. The technical success rate was 100%. Balloon angioplasty of an outflow stenosis was
performed in 56% of stent grafts. The 30- and 180-day patency rate was 100% and 69.2%, respectively. Three secondary
interventions were performed for treatment of unrelated stenosis. Treatment failure occurred in five (18.5%) stent grafts
due to infection (n  3) and thrombosis (n  2). Treatment of PSA with skin erosion was associated with failure due to
infection (odds ratio, 5.0; 95% confidence interval, .38, 66.01). The remaining 22 (81.5%) stent grafts remain patent. The
mean follow-up time was 268.9 days (median, 97.5).
Conclusions: Endovascular therapy is an effective and durable treatment option for patients with dialysis access PSAs. This
technique permits immediate use of the hemodialysis access site as well as identification and treatment of associated
stenosis. It may be considered as an alternative to open repair in patients who are anatomically suitable candidates.





















uEnd-stage renal disease is becoming increasingly com-
mon in the United States with an aging population. Data
from the U.S. Renal Data System in 2005 indicated that
more than 106,000 new patients began treatment for end-
stage renal disease, and that approximately 341,000 pa-
tients were receiving dialysis.1 The Society for Vascular
Surgery published clinical guidelines in 2008 for the surgi-
cal placement and maintenance of arteriovenous hemodial-
ysis access to optimize and prolong use of such access.2
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1058Pseudoaneurysm (PSA) formation is a known compli-
ation of hemodialysis arteriovenous grafts (AVGs) and
stulas (AVFs), which is associated with an increased risk of
hrombosis, bleeding, infection, pain, and failure of at-
empted hemodialysis.3 It has been reported to occur in 2%
o 10% of AVGs, with a lower incidence in fistulas.4,5
urgical repair often requires pseudoaneurysm resection
ith interposition graft placement, and insertion of a tun-
eled hemodialysis catheter to serve as a bridge for several
eeks until the graft is ready for use (Figs 1 and 2).
ndovascular stent graft repair of pseudoaneurysms is a
inimally invasive alternative, which can prolong the dura-
ility of jeopardized AVFs and AVGs and also permits
mmediate use of the hemodialysis access site. The objective
f this study was to determine the effectiveness of stent
rafts for repair of pseudoaneurysms associated with AVFs
nd AVGs.
ETHODS
A retrospective review of medical records at our univer-
ity affiliated institution was performed. From October
007 to March 2011, 24 patients with a hemodialysis AVF
r AVG pseudoaneurysm underwent endovascular repair
sing a commercially available self-expandable covered
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complications.
All procedures were performed under either regional or
general anesthesia in a hybrid endovascular operating suite
with a Leonardo Siemens angiographic fluoroscopy unit
programmed with precalibration for measurements. All
patients received prophylactic intravenous antibiotics prior
to administration of anesthesia. The AVG or AVF was
cannulated percutaneously from a site several centimeters
remote from the pseudoaneurysm utilizing a micropunc-
ture technique and a 5F angiographic catheter was then
inserted.
A diagnostic antegrade or retrograde fistulagram was
obtained to evaluate the hemodialysis access, including the
arterial anastomosis and native outflow veins as well as the
central venous system. Measurements of the proximal and
Fig 1. Intraoperative photo of patient with two large pseudoan-
eurysms (PSAs) undergoing open surgical repair with resection
and polytetrafluoroethylene (PTFE) interposition graft placement.
Fig 2. Completion photo of patient with two large pseudoaneu-
rysms (PSAs) undergoing open surgical repair with resection and
polytetrafluoroethylene (PTFE) interposition graft placement.distal landing zone diameters associated with the PSAs as tell as the length of the PSAs were then obtained. Stent
raft diameter was chosen by oversizing the landing zone
iameter by approximately 10% to 15%. The stent graft
ength was determined by allowing for coverage of 1- to
-cm segments of normal landing zone both proximal and
istal to the PSA.
Only patients whomet anatomic criteria and had a neck
f adequate diameter and length proximal and distal to the
SA were considered for endovascular repair. Devices used
ere the Viabahn stent graft (W. L. Gore and Associates,
lagstaff, Ariz) and Fluency Plus stent graft (Bard Inc,
empe, Ariz). The Viabahn stent graft is available in diam-
ters from 5 to 15 mm and the Fluency stent graft in
iameters from 6 to 10 mm. This allowed treatment of
SAs with neck diameters ranging from 4 to 13 mm.
Approximately 50 units/kg of intravenous heparin was
dministered systemically. The stent grafts were then intro-
uced over a 0.35-inch hydrophilic glide wire via a sheath
anging from 7F to 12F diameter. The type of stent graft
elected was based on the surgeon’s preference. Post-
eployment balloon dilation of the stent graft was per-
ormed to fully seal the device within the fistula or graft
umen. A completion fistulagramwas performed to confirm
ig 3. Diagnostic fistulagram in a patient demonstrating two
seudoaneurysms (PSAs) with diameters of 23.1mm and 31.1mm
ndergoing endovascular repair.
ig 4. Completion fistulagram following deployment of a
0-mm by 15-cm stent graft demonstrating adequate proximal
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mal or distal to the pseudoaneurysm was also performed.
The heparin effect was then fully reversed with protamine
sulfate. The sheath insertion site was closed using a 4-0
polypropylene purse string suture. The dialysis centers were
instructed to cannulate the AVFs or AVGs in areas remote
from the pseudoaneurysms for 30 days.
For all categorical variables, percentages were calcu-
lated. For continuous variables, we calculated their means
(standard deviations) and/or medians (ranges). A Fisher
exact test was used to determine whether there was an
association between two categorical variables. A Kaplan-
Meier curve for stent graft patency was created by using
survival analysis. All the statistical analyses were conducted
by using software SAS 9.1 (SAS; SAS Institute, Gary, NC).
RESULTS
Twenty-seven self-expanding covered stent grafts (Via-
bahn, W. L. Gore, n 25; Fluency, Bard, n 2) were used
to treat hemodialysis access PSA (AVG, n  13; AVF, n 
11) in 24 patients. Indications for repair included PSA with
symptoms of swelling or discomfort (n  11), PSA with
skin erosion (n 8), PSA with failed hemodialysis (n 3),
and PSA caused by balloon angioplasty of a stenotic lesion
(n  2). There were 16 females, eight males, with a mean
age of 55.7 years, mean body mass index of 28.4. Comor-
Fig 5. Kaplan-Meier estimate ofbidities included hypertension (n  22; 91.67%), diabetes uellitus (n  8; 33.33%), and coronary artery disease (n
; 16.67%). The median time from hemodialysis access
reation to PSA repair was 455 days. Twenty-five percent
n  6) of patients underwent angioplasty of a stenosis
rior to presenting for PSA repair. The mean diameter of
he treated PSA was 19.5 (10.0) mm. The technical
uccess rate was 100%. Balloon angioplasty of a separate
tenotic lesion was performed at the time of PSA repair in
0 out of 27 (74.1%) stent grafts. In 15 out of 27 (56%),
alloon angioplasty of an outflow stenosis was performed.
e did not initiate antiplatelet or warfarin therapy after
ndovascular repair of PSAs. The patients continued all
revious medications after the procedure. At the time of
SA repair, 16 out of 24 (66.7%) patients were taking either
ntiplatelet therapy (11 out of 24 patients) or warfarin
nticoagulation (six out of 24 patients).
Simultaneous open surgical decompression was per-
ormed on two patients with PSA diameter 4 cm after
tent graft placement. All patients were able to undergo
mmediate hemodialysis without the need for a bridging
emodialysis catheter. Overall stent graft patency was
1.5% (22 out of 27 stent grafts patent) with a mean
ollow-up of 268.9 days (median, 97.5 days). Three sec-
ndary interventions were performed at 65, 233, and 345
ays following stent graft placement for treatment of an
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of the probability of stent graft success is shown in Fig 5.
Treatment failure occurred in five patients who under-
went endovascular stent graft repair of PSA (18.5% of stent
grafts) due to infection (n  3) and thrombosis (n  2)
(Table).
Among the three patients with infected grafts, one
patient presented with an open wound and exposed stent
graft. This was resected and replaced with an interposition
graft tunneled through unaffected tissue. The patient is
currently using this access site without difficulty. The sec-
ond patient presented with ulcerative skin lesions and pos-
itive wound cultures, while the third patient presented with
sepsis. These grafts were both excised entirely. Both pa-
tients require new access sites.
Treatment of PSAwith skin erosion was associated with
failure due to infection (odds ratio, 5.0; 95% confidence
interval, .38, 66.01). Of the eight patients treated with skin
erosions, there were two failures due to infection (25%) and
one failure due to graft thrombosis (12.5%). The failure
rate was 30.8% (four out of 13) among patients with AVGs
and 9.1% (one out of 11) among patients with AVFs.
Treatment of patients with PSA in AVGs was associated
with failure (odds ratio, 4.2; 95% confidence interval, .33,
240; P value from Fisher exact is .3271). All of the failures
due to infection occurred in patients with AVGs.
DISCUSSION
Our findings demonstrate that the endovascular treat-
ment of hemodialysis access PSAs with self-expanding cov-
ered stent grafts is an effective and durable treatment
option. It is a less invasive alternative to the conventional
open surgical approach of PSA resection and replacement
with an interposition graft, which frequently requires inser-
tion of a tunneled hemodialysis catheter to act as a bridge
until the access site is ready for use. Endovascular treatment
as we have described obviates the need for a bridging
hemodialysis catheter. In our series, the access site was able
to be successfully used for hemodialysis immediately fol-
lowing PSA repair in all cases. There were no complications
associated with early puncture of the stent grafts during
hemodialysis.
Others investigators have also reported successful he-
Table. Causes of stent graft failure in five patients with










AV graft Skin erosion 34 Infection
AV graft Skin erosion 69 Infection
AV fistula Symptoms 77 Thrombosis
AV graft Skin erosion 126 Thrombosis
AV graft Symptoms 644 Infection
AV, Arteriovenous; PSA, pseudoaneurysm.modialysis within 24 to 48 hours in patients receiving pallgraft (Boston Scientific Corporation, Natick, Mass),
iabahn, and Fluency stent grafts for AVG PSA.6,7 In an
nimal model utilizing domestic swine, AVG PSAs treated
ith Wallgraft stents underwent dialysis by directly cannu-
ating the PSA through the stent graft 1 week following
tent graft placement and then every 4 days for 6 weeks.8
he authors found perigraft leaks on color flow duplex
canning immediately following dialysis with leak rates
ecreasing from 72% to 33% from 1 to 6 weeks following
ndovascular treatment. However, no evidence of perigraft
eak was identified when duplex scanning was performed 24
ours following each hemodialysis session. The authors
ostulated that the transient perigraft leaks may have been
elated to anticoagulation given at the time of dialysis.
One important advantage of endovascular repair in-
ludes the ability to identify and treat concomitant stenoses
t the time of pseudoaneurysm exclusion. In describing the
emodynamics of failing dialysis grafts, Sullivan et al re-
orted that a stenosis of 40% is associated with a statisti-
ally significant rise in graft pressure.9 In our series, balloon
ngioplasty of an outflow stenosis was performed in associa-
ion with 56% of all stent grafts implanted for PSAs. This may
redispose to PSA formation, particularly in the setting of
epeated needle puncture of an access site. Histopathologic
nalysis of expanded polytetrafluoroethylene (ePTFE) has
hown the microporous structure of the graft wall to be
isrupted by needle punctures.10 Another contributing factor
o PSA formation in our series may have been that two-thirds
f patients were being treated with antiplatelet therapy or
nticoagulation at the time of PSA repair.
The use of endovascular stenting for the maintenance
f hemodialysis access and treatment of stenotic lesions was
nitially reported by Zollikofer et al in 1988.11 Selby et al
escribed the treatment of hemodialysis fistula PSA with
etachable balloons to induce thrombosis within the
SAs.12 Early reports of the use of covered stents to treat
ngioplasty-induced ruptures and pseudoaneurysms in he-
odialysis access described the use of a nitinol stent (Cragg
ndopro) covered with thin Dacron.13,14 There was a high
ecurrence rate of aneurysms which was attributed to re-
eated puncture of the stent grafts.14 Following the intro-
uction of covered stent grafts, other investigators have
lso described their use for the treatment of hemodialysis
ccess PSA.3,6-8,15,16 We believe our study represents the
argest single institution experience that has been published
o date.
Treatment of PSAwith skin erosion was associated with
ailure due to infection in our analysis. Twenty-five percent
two out of eight) of patients undergoing PSA repair for
kin erosions had their grafts subsequently explanted due to
nfection at 34 and 69 days following treatment. This may
e indicative of bacterial colonization of the PSA cavity at
he time of treatment. We do not believe that this repre-
ents a contraindication to endovascular therapy as the
ajority of patients with skin erosions (62.5%) had a favor-
ble outcome. There was a higher failure rate in patients
ith AVGs (30.8%) vs AVFs (9.1%) with treatment of
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which may be due to the presence of exogenous conduit.
Endovascular stent graft exclusion of PSA does not pre-
clude open surgical repair at a later time if it becomes
necessary.
We recognize that there are limitations to our study. It
is a retrospective analysis with a limited sample size. Al-
though follow-up data was available for all patients, the
mean follow-up was only 269 days. Finally, the stent grafts
used for the treatment of hemodialysis access PSAs are not
approved for this indication by the United States Food and
Drug Administration.
CONCLUSIONS
Endovascular therapy is an effective and durable treat-
ment option for patients with dialysis access PSAs. This
technique permits immediate use of the hemodialysis access
site as well as identification and treatment of associated
stenosis. It may be considered as an alternative to open
repair in patients who are anatomically suitable candidates.
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